Mesoblast completes private placement

New york, april 25, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to mesoblast's existing major us, uk, and australian shareholders raising approximately us$40 million, net of transaction costs, at a$0.85 per share.
MESO Ratings Summary
MESO Quant Ranking